Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone760-260-8600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$164.25 million
Profitability
Miscellaneous
Employees214
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable
Retrophin (NASDAQ:RTRX) Frequently Asked Questions
What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
How were Retrophin's earnings last quarter?
Retrophin Inc (NASDAQ:RTRX) released its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.41. The biopharmaceutical company had revenue of $39.57 million for the quarter, compared to analysts' expectations of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. Retrophin's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.14) earnings per share. View Retrophin's Earnings History.
When is Retrophin's next earnings date?
What price target have analysts set for RTRX?
6 brokerages have issued 1-year target prices for Retrophin's stock. Their forecasts range from $36.00 to $57.00. On average, they anticipate Retrophin's stock price to reach $45.6667 in the next year. This suggests a possible upside of 126.2% from the stock's current price. View Analyst Price Targets for Retrophin.
What is the consensus analysts' recommendation for Retrophin?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.
Has Retrophin been receiving favorable news coverage?
News coverage about RTRX stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Retrophin earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Retrophin.
Are investors shorting Retrophin?
Retrophin saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 4,368,200 shares, an increase of 9.4% from the April 15th total of 3,991,400 shares. Based on an average daily trading volume, of 396,300 shares, the days-to-cover ratio is presently 11.0 days. Approximately 13.7% of the company's shares are sold short. View Retrophin's Current Options Chain.
Who are some of Retrophin's key competitors?
Some companies that are related to Retrophin include Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Uniqure (QURE), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Arrowhead Pharmaceuticals (ARWR), Reata Pharmaceuticals (RETA), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Myokardia (MYOK) and Insmed (INSM).
What other stocks do shareholders of Retrophin own?
Who are Retrophin's key executives?
Retrophin's management team includes the folowing people:
- Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
- Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
- Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
- Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
- Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)
Who are Retrophin's major shareholders?
Retrophin's stock is owned by a number of of institutional and retail investors. Top institutional investors include The Manufacturers Life Insurance Company (4.69%), Handelsbanken Fonder AB (1.12%), Sphera Funds Management LTD. (1.05%), Spark Investment Management LLC (0.77%), Oak Ridge Investments LLC (0.64%) and PNC Financial Services Group Inc. (0.57%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.
Which institutional investors are selling Retrophin stock?
RTRX stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., First Trust Advisors LP, Oak Ridge Investments LLC, Quantitative Systematic Strategies LLC, Bank of Montreal Can, Falcon Point Capital LLC, California Public Employees Retirement System and American International Group Inc.. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.
Which institutional investors are buying Retrophin stock?
RTRX stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., The Manufacturers Life Insurance Company, Spark Investment Management LLC, Handelsbanken Fonder AB, Emory University, Mercer Global Advisors Inc. ADV, Campbell & CO Investment Adviser LLC and SG Americas Securities LLC. View Insider Buying and Selling for Retrophin.
How do I buy shares of Retrophin?
Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Retrophin's stock price today?
One share of RTRX stock can currently be purchased for approximately $20.19.
How big of a company is Retrophin?
Retrophin has a market capitalization of $836.67 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.
What is Retrophin's official website?
How can I contact Retrophin?
Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]
MarketBeat Community Rating for Retrophin (NASDAQ RTRX)
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
